Open roles at Superluminal Medicines
Latest Superluminal Medicines Signals
What they do
Superluminal Medicines has raised an oversubscribed $60 million in Series B financing, led by BVF Partners, to advance its lead obesity program into clinical development and expand its AI-enabled drug discovery platform. New investors Deep Track Capital and Perceptive Advisors joined existing investors including RA Capital Management, Insight Partners, NVIDIA, Catalio Capital Management, Eli Lilly and Company, Cooley, and Gaingels.
Why it matters
Superluminal is developing a selective, biased MC4R agonist aimed at treating rare genetic forms of obesity and hypothalamic obesity. The company leverages an AI-enabled drug discovery platform that integrates structural biology and machine learning to create small-molecule therapeutics with minimized side effects.
Traction
Superluminal is transitioning from a discovery-stage platform to a clinical-stage biotechnology company, with a Phase 1 clinical trial for its lead program expected to begin by the end of 2026. The focus on rare genetic obesity conditions highlights a target market with significant unmet medical needs.
Where the market is going
Superluminal is poised to disrupt the obesity treatment landscape, traditionally dominated by broader, less targeted therapies. By focusing on the MC4R pathway and leveraging advanced AI techniques, the company is betting on a more precise approach that could redefine treatment paradigms for conditions like Bardet-Biedl syndrome and Prader-Willi syndrome.
Why Superluminal Medicines is hiring
Superluminal Medicines closed a $60M funding round in September 2026, with investors including BVF Partners, Deep Track Capital, Perceptive Advisors and others. It currently has 5 open roles, 5 of them posted in the last 30 days, with hiring concentrated in Boston. Companies tend to grow headcount fastest in the months after a round, so now is a good time to apply.
Similar Health companies hiring
Superluminal Medicines jobs: common questions
Is Superluminal Medicines hiring?
Yes. Superluminal Medicines has 5 open roles on SuperAIJobs right now, including 5 posted in the last 30 days. The list is refreshed daily from Superluminal Medicines’s own careers site.
Where are Superluminal Medicines jobs located?
Most open roles at Superluminal Medicines are in Boston.
Does Superluminal Medicines hire remotely?
None of Superluminal Medicines’s current roles are listed as remote, so expect to work from one of its offices.
How much has Superluminal Medicines raised?
The latest round we track is a $60M funding round in September 2026. Investors include BVF Partners, Deep Track Capital, Perceptive Advisors and others. See the full deal history on MapCo.
What does Superluminal Medicines do?
Superluminal is developing a selective, biased MC4R agonist aimed at treating rare genetic forms of obesity and hypothalamic obesity.
How do I apply for a job at Superluminal Medicines?
Every role on this page links straight to Superluminal Medicines’s own application page, so you apply directly — SuperAIJobs never sits in between.